In this article, we will take a look at some of the best NASDAQ stocks under $50 to buy.
In this era where everyone is striving for the best, whether it be something in daily life or technology, the stock market is no exception. There are different measures to label the “best” stocks; however, the most common is a high-return stock.
As the Goldman Sachs Equity Strategy Team cited,
“Stocks with strong upside potential often exhibit a combination of mispricing, durable business models, and the capacity to deliver sustained returns.”
In simple terms, the best stocks are the kind of stocks that are trading below what they are truly worth, exhibiting strong upside potential, and belonging to higher-return markets. With that being said, these stocks may not necessarily be market favorites with high prices; sometimes, these are just the ones the market hasn’t fully realized yet. With investors showing an inclination toward growth stocks, we will take a look at some of the best NASDAQ stocks to consider.
Our Methodology
In compiling the list of stocks, we have considered stocks having a record of market outperformance, with high price targets by analysts. From technology to pharmaceuticals, these stocks belong to high-growth, diverse sectors. These companies are then listed according to the upside potential, calculated through the one-year price targets by Yahoo Finance, from lowest to highest.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. TTM Technologies, Inc. (NASDAQ:TTMI)
Upside potential as of June 16, 2025: 2.45%
Stifel has maintained a Buy rating on TTM Technologies, Inc. (NASDAQ:TTMI), while raising the price target to $40 from $33 due to the company’s solid performance in key sectors, including aerospace, defense, and data centers.
Recently, the financial services company hosted Thomas Edman, the President and CEO of TM, and Sameer Desai, the VP of Corporate Development and Investor Relations, at its 2025 Stifel CSI Conference. Considering the returns, the giant has consistently outperformed the market. While the one-year return by the broader market stands at 11.07%, TTM Technologies, Inc. (NASDAQ:TTMI) delivered an impressive 105.37% return. Similarly, the three-year and five-year returns by TTMI surpass the market by 131.24% and 119.39%, respectively.
The effort to shift to more stable and higher-margin markets is certainly paying off. But the real intrigue lies in the giant’s role in the next wave of defense projects, particularly the Golden Dome missile defense system. By 2026, U.S. defense spending will exceed the $1 trillion mark, and this means more popularity of companies providing defense electronics.
TTM Technologies, Inc. (NASDAQ:TTMI) is a California-based manufacturer of technology solutions, mainly mission systems, radio frequency (RF) components and RF microwave/microelectronic assemblies, and printed circuit boards (PCB). Founded in 1978, the company is focused on delivering superior value.
9. Rocket Lab Corporation (NASDAQ:RKLB)
Upside potential as of June 16, 2025: 5.05%
Analysts at Cantor Fitzgerald have reaffirmed their Overweight rating and $35.00 price target on Rocket Lab Corporation (NASDAQ:RKLB), implying a 35% upside from the current levels. This optimism stems from the investor meetings across Europe in the past week, where topics like Electron’s launch cadence, Neutron rocket development, and the space systems segment were discussed.
The firm noted that the company’s recent initiatives speak volumes regarding its prospects. Rocket Lab Corporation (NASDAQ:RKLB) possesses a competitive edge against SpaceX, its latest acquisitions of Mynaric and Geost, as well as talks around President Trump’s Golden Dome Initiative. Additionally, the successful execution of 66 space launches adds an extra layer of excellence.
With a market capitalization of $11.91 billion, Rocket Lab Corporation (NASDAQ:RKLB) was regarded by the leading investment firm during its assessment as an “end-to-end space company that is best-positioned in the industry.” What’s even more exciting is that the company is a potential beneficiary of the public disagreement between President Trump and Elon Musk.
Rocket Lab Corporation (NASDAQ:RKLB) is a California-based company that provides launch services and space systems solutions. Founded in 2006, the core offerings of the company include launch services, spacecraft manufacturing and design, and spacecraft components. The giant is aimed at leveraging space for innovation.
8. Privia Health Group, Inc. (NASDAQ:PRVA)
Upside potential as of June 16, 2025: 32.61%
Analysts at TD Cowen have named Privia Health Group, Inc. (NASDAQ:PRVA) its “Best Smidcap Idea” while maintaining a Buy rating and a $30.00 price target. This potential surge of about 31% from the current price is driven by the company’s robust financial footing, which includes zero debt and more than $400 million in cash.
Over the years, Privia Health Group, Inc. (NASDAQ:PRVA) has delivered improved results, with PRVA’s 17.08% year-to-date return surpassing the market’s 2.58% return. The leading investment bank believes that the company possesses the potential to deliver more than 20% EBITDA growth not only in 2025 but also in 2026. This is anything but ordinary, given the current market pessimism.
What makes Privia Health Group, Inc. (NASDAQ:PRVA) stand out the most is its capital-light business model that yields positive free cash flow in addition to maintaining impressive EBITDA growth. The analysts believe that this is the perfect blend for the powerhouse’s scalable and predictable business operation.
Privia Health Group, Inc. (NASDAQ:PRVA) is a Virginia-based physician-enablement company that partners with physician practices, health plans, and health systems to provide technology and population health tools. Founded in 2007, the company also manages an accountable care organization for enhanced coordination and patient quality metrics.
7. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Upside potential as of June 16, 2025: 44.64%
On Monday, analysts at TD Cowen reaffirmed their Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), expressing confidence in the company’s mitapivat drug ahead of trial results.
The financial services firm believes that the drug will show considerable reductions in vaso-occlusive crises (VOCs) during the Phase 3 RISE-UP trial for sickle cell disease (SCD), with full results expected by the end of this year. With SCD’s sales potential of $4 billion, TD Cowen highlights the company’s position in this emerging market.
The company was also named TD Cowen’s top small to mid-cap pick as it views positive Phase 3 trial results to be the turnaround point for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Having said that, the stock price could rise by as high as 100% by the year’s end. With the lead candidate FDA-approved and two more on the horizon, achieving the price target set by analysts doesn’t seem impossible.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company incorporated in 2007. This Massachusetts-based company engages in the discovery and development of treatments in the area of cellular metabolism. With PYRUKYND (mitapivat) as its lead candidate, the giant aims to elevate and extend the lives of many.
6. NeuroPace, Inc. (NASDAQ:NPCE)
Upside potential as of June 16, 2025: 54.37%
Cantor Fitzgerald reiterated its Overweight rating on NeuroPace, Inc. (NASDAQ:NPCE), with a price target of $16.00, implying an upside of nearly 44%. This affirmation is based on a survey of medical professionals about the giant’s RNS System.
The survey, conducted among 30 medical professionals, including epileptologists, neurologists, and neurosurgeons, assessed perceptions regarding the potential FDA approval and adoption of the RNS System for idiopathic generalized epilepsy (IGE). The results raised the firm’s confidence in NeuroPace, Inc. (NASDAQ:NPCE).
With a one-year return surpassing the market’s return by 60.82%, NeuroPace, Inc. (NASDAQ:NPCE) is certainly heading north. The company is developing responsive neurostimulation technology to detect specific brain activity patterns related to seizures. The current RNS System is approved for particular kinds of epilepsy, with the potential IGE indication highlighting its total addressable market (TAM).
NeuroPace, Inc. (NASDAQ:NPCE), founded in 1997, is a medical device company in the United States. The company develops RNS systems and provides physician tablets and patient data management systems. The company is aimed at transforming the lives of people living with epilepsy.
5. Alphatec Holdings, Inc. (NASDAQ:ATEC)
Upside potential as of June 16, 2025: 66.25%
On Monday, analysts at Lake Street Capital Markets initiated a high-note coverage on Aphatec Holdings with a Buy rating and price target of $18, implying a solid jump of 63% from its current trading price of $11.02.
What’s driving the optimistic outlook? As Lake Street highlights,
“Alphatec Holdings, Inc. (NASDAQ:ATEC) represents the only scaled spine player totally focused on improving spine outcomes while much of the industry borders on totally confused.”
This positive coverage followed a non-deal roadshow in New York City, where Alphatec’s management and Lake Street analysts met to discuss the company’s goals and strategic plans. The investment bank believes that the company will continue to surpass growth rates driven by a focus on a niche spine treatments market. This is reinforced by the 20.04% year-to-date return delivered by the giant in contrast to the return of merely 2.58% by the broader market.
Alphatec Holdings, Inc. (NASDAQ:ATEC) is a California-based medical technology company that engages in the design and advancement of surgical treatment of spinal disorders technologies. Founded in 1990, the core offerings of the company include the Alpha InformatiX product platform, VEA alignment mobile application, and PTP Patient Positioning Systems. The company aims to become “The Standard-Bearer in Spine.”
4. Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Upside potential as of June 16, 2025: 73.23%
On Monday, analysts at Goldman Sachs started coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) with a Buy rating and a $37.00 price target, implying a rise of about 60% from the current levels. The firm’s confidence in the stock stems from favorable Phase 1 data for the company’s chronic myeloid leukemia (CML) solution.
The investment bank noted that ELVN-001’s sustained efficacy data, presented during the European Hematology Association meeting, highlighted a 47% overall cumulative major molecular response (MMR) rate by 24 weeks and a 41% response in tyrosine kinase inhibitor (TKI)-resistant patients. These results surpassed the fourth-generation Scemblix by Novartis (SIX:NOVN) figures, with a difference of 10% and 32%, respectively.
The company is all set to launch a Phase 3 trial in 2026, which in itself is a $3 billion opportunity. If we look at the three-year return, Enliven Therapeutics, Inc. (NASDAQ:ELVN) exhibited a return of a whopping 1,980.18% in contrast to the 64.53% return by the market. Calling this simply an “amazing” performance would be an understatement.
Enliven Therapeutics, Inc. (NASDAQ:ELVN), headquartered in Boulder, Colorado, is a clinical-stage biopharmaceutical company. The company focuses on the recognition and development of small-molecule inhibitors to assist people living with cancer, improving survival and overall well-being.
3. UroGen Pharma Ltd. (NASDAQ:URGN)
Upside potential as of June 16, 2025: 139.75%
On Monday, analysts at H.C. Wainwright significantly raised the rating for UroGen Pharma Ltd. (NASDAQ:URGN) to Buy from Neutral, with a price target of $50.00. This revision was after Thursday’s regulatory approval of Zusduri, priced at $21,500 per dose.
With the stock price increasing by over 100% in the past five days and the potential to rise even further, investors have little to worry about. UroGen Pharma Ltd. (NASDAQ:URGN), exhibiting an impressive gross margin of around 90%, is set for a product launch aimed at non-muscle invasive bladder cancer, which affects as many as 59,000 patients annually in the U.S. alone. By 2026, the treatment is anticipated to achieve expected performance, generating $1 billion in sales.
While clarity around the approval path for UGN-103 is sought by the analysts, the management believes potential changes to the clinical trial strategy insignificantly impact its financial outlook. Having said that, UGN-103 is crucial for advancing the giant’s franchise exclusivity beyond early 2031.
UroGen Pharma Ltd. (NASDAQ:URGN) is a clinical-stage biopharmaceutical company founded in 2004. This New Jersey-based company develops and markets treatments for urothelial and specialty cancers. The company’s core offerings include RTGel and Jelmyto, with UGN-102, UGN-103, and UGN-104 being the lead product candidates.
2. Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Upside potential as of June 16, 2025: 316.74%
Analysts at H.C. Wainwright have reaffirmed a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while maintaining a price target of $30.00. This whopping 237% upside from the current price followed the company’s positive three-year data for its hereditary angioedema (HAE) treatment presentation at the European Academy of Allergy and Clinical Immunology meeting.
What emerged from the findings was truly impressive. The Phase 1 trial data demonstrated that a single dose of lonvoguran ziclumeran (lonvo-z, or NTLA-2002) resulted in a 98% mean reduction in monthly HAE attack rates in all 10 patients evaluated.
The treatment maintained effectiveness throughout the three years, with sustained effects noted across the study. These results are in sync with the nature of gene editing, which is designed to produce lasting changes to the genome.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a Massachusetts-headquartered clinical-stage gene editing company. The giant develops curative genome editing treatments. In collaboration with AvenCell Therapeutics, Inc., the company aims to create innovative therapies for a range of diseases.
1. Prothena Corporation plc (NASDAQ:PRTA)
Upside potential as of June 16, 2025: 329.09%
Roche, a partner of Prothena Corporation plc (NASDAQ:PRTA), has announced plans to initiate Phase 3 development of prasinezumab for early-stage Parkinson’s disease. Although the company faced a setback with birtamimab, which failed to meet the desired result, the giant is keen on taking things forward with new developments.
This decision comes after the company’s favorable Phase 2b PADOVA results and sustained follow-up data highlighting clinical benefit when prasinezumab solution and symptomatic treatment are used together. This creates exciting opportunities for the company, which has a potential upside of over 300%, as the one-year price target of $24.29 by Yahoo Finance suggests.
One thing that is most important for companies such as Prothena Corporation plc (NASDAQ:PRTA) is the determination to stand strong despite failures. The company’s strong pipeline, including Alzheimer’s, Parkinson’s, and ATTR-CM candidates, makes us believe that achieving the upside potential isn’t hard to achieve, particularly when the Alzheimer’s Disease market is anticipated to reach $19.3 billion by 2033.
Prothena Corporation plc (NASDAQ:PRTA) is an Ireland-based late-stage clinical biotechnology company that identifies and develops novel therapies for diseases caused by protein dysregulation. Incorporated in 2012, the company focuses on advancing therapies through clinical development, often in collaboration with other organizations.
While we acknowledge the potential of PRTA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PRTA and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
